News
SWTX
44.20
+1.89%
0.82
SpringWorks Therapeutics -- Newly Commercial Stage, Fully Valued Biotech Means Steer Clear
SpringWorks Therapeutics has received FDA approval for Nirogacestat. The company is now facing the challenge of successfully commercializing its therapy. With rapidly growing losses and its hefty market cap, SpringWorks is a "Hold" for now. SpringWorks has entered the commercial stage biotech industry with its lead therapy.
Seeking Alpha · 18h ago
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Barchart · 2d ago
Weekly Report: what happened at SWTX last week (0415-0419)?
Weekly Report · 4d ago
SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners
Seeking Alpha · 6d ago
SpringWorks Therapeutics is Now Oversold (SWTX)
NASDAQ · 6d ago
Weekly Report: what happened at SWTX last week (0408-0412)?
Weekly Report · 04/15 09:12
Weekly Report: what happened at SWTX last week (0401-0405)?
Weekly Report · 04/08 09:13
Weekly Report: what happened at SWTX last week (0325-0329)?
Weekly Report · 04/01 09:13
Weekly Report: what happened at SWTX last week (0318-0322)?
Weekly Report · 03/25 09:12
Weekly Report: what happened at SWTX last week (0311-0315)?
Weekly Report · 03/18 09:13
Weekly Report: what happened at SWTX last week (0304-0308)?
Weekly Report · 03/11 09:12
Big Pharma patent cliffs seen fueling oncology M&A this year
Big Pharma patent cliffs seen fueling oncology M&A this year. Around $182B in revenue is at risk over the next four years due to patent expirations. Cantor Fitzgerald sees between five and 17 acquisition deals for oncologists in 2014. The global market for cancer drugs is expected to grow from $180B in 2022 to $323B in 2028.
Seeking Alpha · 03/10 17:08
Correction to SpringWorks Therapeutics Rating on March 6
JP Morgan raised its price target on SpringWorks to $75.00/share from $74.00. The price target was incorrectly reported to be $73.00 on March 6. The company's stock is now trading at $75 in the U.S.
Dow Jones · 03/08 16:04
5 Biotech Stocks With 26% Upside Potential or More
Five biotech stocks are poised for notable growth. Nvidia (NVDA) is the standout performer in the S&P 500 Index so far this year. The biotech industry may be headed for a comeback. Each of these stocks has room to rally 26% to Wall Street's mean price target.
Barchart · 03/07 13:13
SpringWorks Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/06 13:37
SpringWorks Therapeutics Is Maintained at Overweight by JP Morgan
Dow Jones · 03/06 11:49
SpringWorks Therapeutics Price Target Raised to $74.00/Share From $73.00 by JP Morgan
Dow Jones · 03/06 11:49
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Springworks Therapeutics (SWTX) and Genmab (GMAB)
Immunocore Holdings (IMCR) and Springworks Therapeutics (SWTX) and Genmab (GMAB) have 3 analysts with bullish sentiments on the Healthcare sector. 3 analysts just reiterated a Buy rating on Immunocore and 2 others on Springworks. The 3 stocks are most likely to make moves following insider activities.
TipRanks · 03/06 11:40
JP Morgan Maintains Overweight on SpringWorks Therapeutics, Raises Price Target to $74
Benzinga · 03/06 11:38
U.S. RESEARCH ROUNDUP-Bark, Fleetcor Technologies, Tesla
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Bark, Fleetcor Technologies and Tesla are among the companies. The analysts raised their ratings on Bark and raised their targets for Fleetcor and Tesla. The companies are all listed on the New York Stock Exchange.
Reuters · 03/05 06:57
More
Webull provides a variety of real-time SWTX stock news. You can receive the latest news about Springworks Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SWTX
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. Its ongoing developments include Nirogacestat for treatment of ovarian granulosa cell tumors, Nirogacestat in combination with B-cell maturation antigen (BCMA)-targeted agents, Mirdametinib Phase 2b ReNeu trial in NF1-PN and Brimarafenib (BGB-3245). The Company's early-stage pipeline includes SW-682, an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluated in Hippo-mutant solid tumors.